Drugs / SCRI-huCAR19v1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03684889 | Nov 2018 → Feb 2021 overdue | leukemia, lymphoma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCRI-huCAR19v1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03684889 ↗ |
| Modality | Cell therapy | “1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced” NCT03684889 ↗ |